IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INTERPACE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $138.57M
- P/E (TTM)
- 5.6
- Dividend yield
- –
INTERPACE BIOSCIENCES, INC. revenue by segment
By business segment
| Operating income | TTM Q3 15 | TTM Q2 15 | TTM Q1 15 | TTM Q4 14 | TTM Q3 14 | TTM Q2 14 | TTM Q1 14 | TTM Q4 13 | TTM Q3 13 | TTM Q2 13 | TTM Q1 13 | TTM Q4 12 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Commercial Services [Member] | -$133.00K | -$2.02M | -$2.17M | -$3.17M | – | – | – | – | – | – | – | – | – |
| Marketing Services [Member] | – | – | – | – | -$6.30M | -$6.20M | -$5.03M | -$4.39M | -$27.31M | -$27.46M | -$27.68M | -$27.47M | – |
| Product Commercialization Services [Member] | – | – | – | – | -$2.58M | $52.00K | $1.07M | $1.87M | $2.10M | $2.62M | $2.92M | $3.16M | – |
| Sales Services [Member] | – | – | – | – | -$2.99M | -$3.56M | -$4.07M | -$1.75M | $625.00K | $1.55M | $2.00M | -$930.00K | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Interpace Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.